Ally Bridge Group NY LLC Reduces Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Ally Bridge Group NY LLC lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 39.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,710 shares of the company's stock after selling 93,146 shares during the quarter. Enliven Therapeutics comprises about 2.7% of Ally Bridge Group NY LLC's portfolio, making the stock its 17th largest position. Ally Bridge Group NY LLC owned 0.29% of Enliven Therapeutics worth $3,188,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after buying an additional 199,692 shares during the period. Vanguard Group Inc. lifted its position in shares of Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after purchasing an additional 135,969 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Enliven Therapeutics by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 762,718 shares of the company's stock valued at $17,165,000 after buying an additional 12,510 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in Enliven Therapeutics in the 4th quarter valued at about $15,106,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the sale, the chief executive officer now owns 990,392 shares in the company, valued at $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,751 shares of company stock worth $1,331,288. Corporate insiders own 29.20% of the company's stock.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock traded up $0.66 during mid-day trading on Friday, reaching $20.51. 221,177 shares of the company were exchanged, compared to its average volume of 259,995. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The business has a fifty day moving average of $19.17 and a 200 day moving average of $22.34. The firm has a market cap of $1.01 billion, a P/E ratio of -10.79 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a report on Friday, March 21st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.